← Leaderboards
Christian Kastrup
Versiti Wisconsin, Inc.
$2,909,910
Attributed
$3,637,089
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,637,089 · 2
By mechanism
R01$3,637,089 · 2
Top collaborators
- Matthew J. Flick2 shared
Most similar at Versiti Wisconsin, Inc.
Same institution · by research overlap
- Thomas Calvin Abshire$2,038,181
- Jeremy P Wood$1,431,444
Others in their field
Other Rising Stars on “Prevent”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Melissa Basford · Vanderbilt University Medical Center$37,410,924
- David Annett · Information Management Services, Inc.$34,721,865
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Lee Lichtenstein · Vanderbilt University Medical Center$26,108,724
- Dorota A. Grejner-Brzezinska · University Of Wisconsin-Madison$19,883,568
Research focus
PreventFibrinolysisInnovationPredispositionSeveritiesTraumaHemorrhageIncidenceKnock-DownMortalityProphylacticProteinsSmall Interfering RnaTargeted AgentAcuteGeneticHemostatic AgentsHemostatic FunctionInsightCoagulation ProcessLipid NanoparticleMorbidity - Disease RateCanis FamiliarisCanine Model
Grant awards (5)
Novel mechanisms to limit thrombosis by decreasing fibrinogen or suppressing fibrin matrix formation$720,242
R01 · FY2025 · HL
Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy$718,283
R01 · FY2025 · HL · contact PI
Novel mechanisms to limit thrombosis by decreasing fibrinogen or suppressing fibrin matrix formation$734,117
R01 · FY2024 · HL
Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy$707,172
R01 · FY2024 · HL · contact PI
Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy$757,275
R01 · FY2023 · HL · contact PI